Complete Summary

GUIDELINE TITLE

Screening and management of hyperlipidemia.

BIBLIOGRAPHIC SOURCE(S)

Michigan Quality Improvement Consortium. Screening and management of hyperlipidemia. Southfield (MI): Michigan Quality Improvement Consortium; 2005 Aug. 1 p.

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Michigan Quality Improvement Consortium. Management of hyperlipidemia. Southfield (MI): Michigan Quality Improvement Consortium; 2003 Aug. 1 p.

COMPLETE SUMMARY CONTENT

SCOPE

DISEASE/CONDITION(S)

Hyperlipidemia

GUIDELINE CATEGORY

Management
Risk Assessment
Screening
Treatment

CLINICAL SPECIALTY

Cardiology
Family Practice
Internal Medicine

INTENDED USERS

Advanced Practice Nurses
Health Plans
Physician Assistants
Physicians

GUIDELINE OBJECTIVE(S)

- To achieve significant, measurable improvements in the screening and management of hyperlipidemia through the development and implementation of common evidence-based clinical practice guidelines
- To design concise guidelines that are focused on key management components of hyperlipidemia to improve outcomes

TARGET POPULATION

Patients age ≥18 years with low density lipoprotein (LDL) >100

INTERVENTIONS AND PRACTICES CONSIDERED

Screening/Risk Assessment

1. Initial fasting lipid profile (total, low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides)
2. Assessment of major risk factors and coronary heart disease (CHD) risk factors
3. Calculation for short-term risk using Framingham projection of 10-year absolute risk

Management/Treatment

1. Patient/family education including risk factor modification
2. Pharmacologic intervention
3. Referral to lipid specialist, if necessary

MAJOR OUTCOMES CONSIDERED

Not stated

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The Michigan Quality Improvement Consortium (MQIC) project leader conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies and existing protocols and/or clinical practice guidelines on the selected topic. A database such as MEDLINE and two to three other databases are used.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Levels of Evidence for the Most Significant Recommendation

A. Randomized controlled trials
B. Controlled trials, no randomization
C. Observational studies
D. Opinion of expert panel

METHODS USED TO ANALYZE THE EVIDENCE

Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Using the health plan guideline summaries and information obtained from the literature search, the Michigan Quality Improvement Consortium (MQIC) director and/or project leader prepare a draft guideline for review by the MQIC Medical Directors.

The draft guideline and health plan guideline summaries are distributed to the MQIC Medical Directors for review and discussion at their next committee meeting.

The review/revision cycle may be conducted over several meetings before consensus is reached. Each version of the draft guideline is distributed to the MQIC Medical Directors, Measurement, and Implementation committee members for review and comments. All feedback received is distributed to the entire membership.

Once the MQIC Medical Directors achieve consensus on the draft guideline, it is considered approved for external distribution to practitioners with review and comments requested.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

External Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Once the Michigan Quality Improvement Consortium (MQIC) Medical Directors achieve consensus on the draft guideline, it is considered approved for external distribution to practitioners with review and comments requested.

The MQIC director also forwards the approved guideline draft to presidents of the appropriate state medical specialty societies for their input. All feedback received from external reviews is presented for discussion at the next MQIC Medical Directors Committee meeting. In addition, physicians are invited to attend the committee meeting to present their comments.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The level of evidence grades (A-D) are provided for the most significant recommendations and are defined at the end of the "Major Recommendations" field.

Risk Assessment

- Screening: Initial fasting lipid profile (i.e., total, low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides); if normal repeat at least every five years [D]
- Treatment is based on LDL, major risk factors, and presence of coronary heart disease (CHD) or equivalent.

Major Risk Factors

- Cigarette smoking
- Hypertension (blood pressure [BP] ≥140/90)
- On antihypertensives, regardless of current BP levels
- HDL: <40 (HDL ≥60 = negative risk factor)
- Family history (first degree) of premature CHD (men <55 years; women <65 years)
- Age (men ≥45 years; women ≥55 years)

CHD Risk Equivalents

- Other clinical forms of atherosclerotic disease (e.g., peripheral arterial disease, abdominal aortic aneurysm, and/or symptomatic carotid artery disease)
- Diabetes
- Multiple risk factors confer a 10-year risk for CHD >20%
- CHD and CHD risk equivalents give a >20% risk of a CHD event within 10 years

Risk Stratification

- Calculate short-term risk for patients with 2+ risk factors using the Framingham projection of 10-year absolute risk [D]:

Categorical Risk	Goal for LDL
CHD or CHD risk equivalents 10-year risk: >20%	<100 mg/dL
2+ risk factors 10-year risk: ≤20%	<130 mg/dL
0-1 risk factor	<160 mg/dL

Education and Risk Factor Modification

Educate patient/family regarding Therapeutic Lifestyle Changes (TLC).

- Reduce saturated fats and cholesterol [A], increase plant stanols/sterol (e.g., cholesterol-lowering margarines), increase viscous soluble fiber (e.g., oats, barley, lentils, beans).
- Decrease weight and increase exercise to moderate level of activity for 30 minutes most days of the week [A].

Pharmacologic Interventions

- TLC and/or drug therapy may be initiated based on the LDL level and/or presence of CHD risk or CHD risk factors.
- Consider drug therapy when the LDL is not at goal by 6 to 8 weeks after TLC has begun in earnest.
- Statins are the most commonly used lipid-lowering agents. Liver function test monitoring is recommended for 12 weeks following treatment initiation, or dosage increases, of any statin.
- Evaluate and adjust drug therapy at 6 to 8 week intervals.
- For patients who do not reach LDL goal, consider referral to lipid specialist.

Definitions:

Levels of Evidence for the Most Significant Recommendation

A. Randomized controlled trials
B. Controlled trials, no randomization
C. Observational studies
D. Opinion of expert panel

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence is provided for the most significant recommendations (See "Major Recommendations" field).

The guideline is based on the 2002 National Cholesterol Education Program (NCEP) Expert Panel Report on Detection, Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (www.nhlbi.nih.gov).

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for hyperlipidemia, Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.

POTENTIAL HARMS

Not stated

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

This guideline lists core management steps. Individual patient considerations and advances in medical science may supersede or modify these recommendations.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

When consensus is reached on a final version of the guideline, a statewide mailing of the approved guideline is completed. The guideline is distributed to physicians in the following medical specialties:

- Family Practice
- General Practice
- Internal Medicine
- Other Specialists for which the guideline is applicable (e.g., endocrinologists, allergists, pediatricians, cardiologists)

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness

IOM DOMAIN

Effectiveness
Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Michigan Quality Improvement Consortium. Screening and management of hyperlipidemia. Southfield (MI): Michigan Quality Improvement Consortium; 2005 Aug. 1 p.

ADAPTATION

The guideline is based on the 2002 National Cholesterol Education Program (NCEP) Expert Panel Report on Detection, Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (www.nhlbi.nih.gov).

DATE RELEASED

2003 Aug (revised 2005 Aug)

GUIDELINE DEVELOPER(S)

Michigan Quality Improvement Consortium

SOURCE(S) OF FUNDING

Michigan Quality Improvement Consortium

GUIDELINE COMMITTEE

Michigan Quality Improvement Consortium Medical Director's Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Physician representatives from participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, and Michigan Peer Review Organization

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Michigan Quality Improvement Consortium. Management of hyperlipidemia. Southfield (MI): Michigan Quality Improvement Consortium; 2003 Aug. 1 p.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the Michigan Quality Improvement Consortium Web site.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on April 14, 2004. The information was verified by the guideline developer on July 27, 2004. This NGC summary was

update by ECRI on November 28, 2005. The updated information was verified by the guideline developer on December 19, 2005.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

Date Modified: 9/25/2006